Hypoxic-Ischemic Encephalopathy clinical trials at University of California Health
3 in progress, 2 open to eligible people
Levetiracetam in the Treatment of Neonatal Seizures
open to eligible people ages up to 1 month
The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than…
at UCSD
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
open to all eligible people
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios from the Neonatal Seizure Registry and participating site outpatient clinics that aims to evaluate whether and how genes alter the risk of post-neonatal…
at UCSF
Neonatal Seizure Registry - Developmental Functional EValuation
Sorry, in progress, not accepting new patients
The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants that aims to evaluate childhood outcomes after acute symptomatic neonatal seizures, as well as examine risk factors for developmental disabilities…
at UCSF
Our lead scientists for Hypoxic-Ischemic Encephalopathy research studies include Jeff J Gold, M.D. PhD Hannah C Glass, MDCM, MAS.
Last updated: